Could BIOFRONTERA AG ORDINARY SHARES GERMANY (OTCMKTS:BFFTF) Go Down After Its Newest Short Interest Report?

May 17, 2018 - By Harriett Tippett

The stock of BIOFRONTERA AG ORDINARY SHARES GERMANY (OTCMKTS:BFFTF) registered a decrease of 72.99% in short interest. BFFTF’s total short interest was 13,800 shares in May as published by FINRA. Its down 72.99% from 51,100 shares, reported previously. The short interest to BIOFRONTERA AG ORDINARY SHARES GERMANY’s float is 0.05%.

It closed at $8.22 lastly. It is down 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. The company has market cap of $. The Company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin. It currently has negative earnings. The firm is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: